^
Association details:
| Biomarker: | CD276 overexpression |
|---|---|
| Cancer: | Esophageal Squamous Cell Carcinoma |
| Drug: | ifinatamab deruxtecan (DS-7300) (Topoisomerase I inhibitor, B7-H3-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
513O - A phase I/II multicenter, first-in-human study of DS-7300 (B7-H3 DXd-ADC) in patients (pts) with advanced solid tumors
Published date:
09/13/2021
Excerpt:
...report preliminary results from a phase 1/2 trial of DS-7300 in pts with advanced solid tumors....Baseline B7-H3 expression was highly prevalent in the study population....Among 56 pts enrolled, 9 partial responses (PRs; 5 confirmed PRs [2 CRPC, 1 esophageal SCC (ESCC), 1 sqNSCLC, 1 SCLC].
Trial ID:
